Dublin, July 30, 2018 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets By Cancer Type By Diagnosis, Monitoring & Recurrence Testing. 2019-2023 W. Historical Data Including Screening Market Potential Size With Executive And Consultant Guides" report has been added to ResearchAndMarkets.com's offering.
The Diagnostic, Therapy Monitoring, Recurrence Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.
GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures.
The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2023. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers as well as breakouts by Diagnostic, Therapy Monitoring and Recurrence Monitoring.
Key Topics Covered:
1. Introduction and Market Definition 1.1 What is Liquid Biopsy? 1.2 The Sequencing Revolution 1.3 Market Definition 1.3.1 Volumes 1.3.2 Prices 1.3.3 Revenue Market Size 1.4 Methodology 1.4.1 Authors 1.4.2 Sources 1.5 A Spending Perspective on Liquid Biopsy 1.5.1 An Historical Look at Clinical Testing 2. Market Overview 2.1 Players in a Dynamic Market 2.1.1 Academic Research Lab 2.1.2 Diagnostic Test Developer 2.1.3 Genomic Instrumentation Supplier 2.1.3.1 Cell Separation and Viewing Instrumentation Supplier 2.1.4 Pharmaceutical/Reagent Supplier 2.1.5 Independent Testing Lab 2.1.6 Public National/regional lab 2.1.7 Hospital lab 2.1.8 Physician Lab 2.1.9 Audit Body 2.1.10 Certification Body 2.2 Using Biopsies 2.2.1 Cancer 2.2.2 Precancerous conditions 2.2.3 Inflammatory conditions 2.3 Biopsy Sites 2.4 The Situation Today - Biopsy Analysis 2.5 Evidence of Cancer - Liquid Biopsy Technology 2.5.1 The Big Picture on Liquid Biopsy Technology. 2.5.2 The Role of CTCs 2.5.2.1 Types of CTCs 2.5.2.2 CellSearch Detection- Ultimate Sensitivity 2.5.2.3 Epic Sciences Detection- Imaging Takes the Lead 2.5.2.4 Maintrac Detection - The Microscope 2.5.2.5 Other Methods 2.5.3 ctDNA - Going Mainstream? 2.5.4 Exosomes and Micro Vesicles - New Kid on Block 2.5.5 The Multiple Play 2.6 Cancer Treatment Protocol Under Siege 2.6.1 Issues and Limitations to Liquid Biopsy Adoption - Double Diagnostics 2.6.2 The Cancer Screening Market Opportunity 2.6.2.1 GRAIL - What Is It? 2.6.3 Cancer Management vs. Diagnosis 2.6.3.1 The Role of Risk Assessment 2.6.3.2 Managing Therapy 2.6.3.3 Monitoring Disease - What Is It? 2.6.4 Phases of Adoption - Looking Into The Future 2.6.5 The Promise of Liquid Biopsy 2.7 Structure of Industry Plays a Part 2.7.1 Hospital Testing Share 2.7.2 Economies of Scale 2.7.2.1 Hospital vs. Central Lab 2.7.3 Physician Office Lab's 2.7.4 Physician's and POCT 2.8 Profiles of Key Players 2.8.1 Qiagen 2.8.2 Agena Bioscience 2.8.3 Angle plc 2.8.4 ApoCell 2.8.5 Biocept 2.8.6 BioFluidica 2.8.7 Bio-Rad Laboratories 2.8.8 Boreal Genomics 2.8.10 Chronix Biomedical 2.8.11 Clearbridge BioMedics 2.8.12 Cynvenio 2.8.13 Cytolumina Technologies Corp 2.8.14 CytoTrack 2.8.15 Diagnologix LLC 2.8.16 Epic Sciences 2.8.17 Exosome Diagnostics 2.8.18 Exosome Sciences 2.8.19 Fluidigm Corp 2.8.20 Fluxion Biosciences 2.8.21 Genomic Health 2.8.39 GRAIL 2.8.22 Guardant Health 2.8.23 HansaBiomed 2.8.23 Horizon Discovery 2.8.24 iCellate 2.8.25 Illumina 2.8.26 Inivata 2.8.27 Janssen Diagnostics 2.8.28 Molecular MD 2.8.29 Myriad Genetics 2.8.30 Natera 2.8.31 New Oncology 2.8.32 Roche Diagnostics 2.8.33 RainDance Technologies 2.8.34 Rarecells SAS 2.8.35 Silicon Biosystems 2.8.36 Sysmex Inostics 2.8.37 SRI International 2.8.38 Thermo Fisher 2.8.39 Trovagene 2.8.40 Freenome 2.8.41 Personal Genome Diagnostics 2.8.42 MDx Health 2.8.43 Bioarray Genetics 2.8.44 Bio-Techne 2.8.45 Oncocyte 2.8.46 Circulogene 2.8.47 Incell Dx 2.8.48 Integrated Diagnostics 2.8.49 Bio Cartis 2.8.50 Clinical Genomics 2.8.51 OncoDNA 2.8.52 Biodesix Inc. 2.8.53 CellMax Life 3. Market Trends 3.1 Factors Driving Growth 3.1.1 Non Invasive Game Changer 3.1.2 Lower Cost 3.1.3 Greater Accuracy 3.1.4 Wide Range of Potential Uses 3.1.5 Aging Population 3.2 Factors Limiting Growth 3.2.1 Lower prices 3.2.2 Lack of Standards 3.2.3 Protocol Resistance 3.2.4 Initial Adoption Has No Cost Savings 3.3 Instrumentation and Automation 3.3.1 Instruments Key to Market Share 3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development 3.4.1 Next Generation Sequencing Fuels a Revolution 3.4.2 Impact of NGS on pricing 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magneto resistance based assay 4. Liquid Biopsy Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section 4.2 Biodesix Acquires Integrated Diagnostics 4.3 Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx 4.4 Bio-Techne to Acquire Exosome Dx for Up to $575M 4.5 GRAIL Announces Data on Detection of Early-Stage Lung Cancers 4.6 CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests 4.7 Personal Genome Diagnostics Nets $75M in Series B Financing 4.8 Circulogene Licenses Liquid Biopsy Tech to Turkish Lab 4.9 Genomic Health, Cleveland Diagnostics Ink Deal to Commercialize Prostate Cancer Tests 4.10 Biocartis Gets CE Marking for Two Colorectal Cancer Liquid Biopsy Tests 4.11 OncoCyte Q3 Net Loss Swells, Lung Cancer Dx Launch Delayed 4.12 Natera, Aarhus University Collaborate on Liquid Biopsy Study for Colorectal Cancer 4.13 MDxHealth Nine-Month Revenues Up 38 Percent 4.14 Clinical Genomics, MSKCC to Study Rectal Cancer Liquid Biopsy Monitoring 4.15 Collaboration in Japan Using Exosomes for Better Cancer Diagnoses, Treatment 4.16 Cancer MDx Firm Bioarray Genetics Raises $4M 4.17 Biocept Inks US Marketing Deal for Target Selector Liquid Biopsy Tech 4.18 Exosome Diagnostics Launches Evidence Development Study for Prostate Cancer Test 4.19 Angle to Buy Axela, Plans to Raise 12.2M in Share Placement 4.20 Mutation Count in ctDNA Predicts Patient Response to Immunotherapy 4.21 Qiagen, Angle to Comarket Liquid Biopsy Technologies 4.22 Cancer MDx Firm Bioarray Genetics Raises $4M 4.23 Genentech Adapts Microfluidics Sequencing Method for Liquid Biopsy Applications 4.24 OncoDNA Gains UK Reimbursement for OncoStrat&Go 4.25 Sequencing of Circulating Tumor DNA Detects Early Cancers 4.26 RareCyte announces $30M round 4.27 Liquid Biopsies May Never Replace Tissue Biopsies 4.28 Karius reels in $50M to ramp up infectious disease liquid biopsy 4.29 Liquid Biopsy Passes Test for Nasopharyngeal Cancer 4.30 Exosome Diagnostics Launches the MedOncAlyzer Pan-Cancer Panel 4.31 Lonza Acquires HansaBioMed, Invests in Exosomics 4.32 Controversial Test Highlights Precision Medicine Marketing, Regulatory Issues 4.33 Trovagene Announces Agreement with Global Biopharmaceutical Company 4.34 Liquid Biopsy Firms Move Toward Multianalyte Detection 4.35 In a first, China approves Amoy's lung cancer liquid biopsy 4.36 Liquid Biopsy Shows Promise for Colon Cancer 4.37 Bio-Rad Continues to Advance Digital PCR Tech, Liquid Biopsy Tests Into Commercial Clinical Market 4.38 Liquid Biopsy Combo Improved Sensitivity for EGFR Mutations in NSCLC 4.39 Startups race to develop cancer screens from DNA 4.40 Bristol-Myers, NEA drive cancer test player to $75M round 4.41 Dutch Researchers Develop ThromboSeq Test to Detect Lung Cancer 4.42 Avalon GloboCare, Da An Gene Collaborate on Liquid Biopsy Diagnostics 4.43 OncoDNA Inks Russian Distribution Deal With Genext 4.44 Biocept Prices $15M Public Offering 4.45 UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests 4.46 Exact Sciences Shares Drop on Threat From Liquid Biopsy 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. Potential Market Opportunity Sizes 10.1 Cancer Screening by Country: Lung, Breast & Colorectal 10.2 Cancer Screening by Country: Prostate, Other Cancer & All Cancer 10.3 Potential Market Size - Cancer Diagnosis 10.4 Potential Market Size - Cancer Management
For more information about this report visit https://www.researchandmarkets.com/research/x...iquid?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Diagnostics, In Vitro Diagnostics
